

 **PRESS RELEASE**

Sosei Heptares notes publication in prestigious journal *Cell* reviewing the research collaboration with the University of Glasgow

Tokyo, Japan and Cambridge, UK, 24 November 2021 – Sosei Group Corporation (“the Company”; TSE: 4565) notes publication of an extensive review describing ground-breaking research led by Sosei Heptares in collaboration with the University of Glasgow and others in the prestigious journal *Cell*.

The review describes, for the first time, the process of designing a new molecule (HTL9936) to selectively target the muscarinic M1 receptor in the brain and demonstrating, through laboratory preclinical and human clinical studies, the potential of this approach to create superior new drugs to improve cognitive function in Alzheimer’s Disease patients, while minimizing side-effects associated with previous attempts to target the M1 receptor.

View full press release issued by the University of Glasgow [here](#)

– Ends –

Enquiries:

Sosei Heptares – Media and Investor Relations

Hironoshin Nomura, SVP Investor Relations and Corporate Strategy

+81 (0)3 6679 2178 | Hironoshin.Nomura@SoseiHeptares.com

Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures

+81 (0)3 5210 3399 | IR@SoseiHeptares.com

Citigate Dewe Rogerson (for Japanese Media)

Yas Fukuda

+81 (0)3 4360 9234 | Yas.Fukuda@citigatedewerogerson.com

MEDiSTRAVA Consulting (for International Media)

Mark Swallow, David Dible

+44 (0)20 7638 9571 | SoseiHeptares@medistrava.com
